Kasai K, Kameya T, Ono M, Wada C, Kuwao S, Motoori T
Department of Pathology, School of Medicine, Kitasato University, Sagamihara, Japan.
Virchows Arch A Pathol Anat Histopathol. 1990;417(1):57-65. doi: 10.1007/BF01600110.
The expression of T-cell receptors (TCR) in malignant lymphomas was examined immunohistochemically by monoclonal antibodies which react with the TCR beta or TCR delta chain. TCR beta was expressed in 16 out of 47 non-Hodgkin's lymphomas. These included 15 T-cell lymphomas and 1 Ki-1 lymphoma. The anti-TCR beta chain antibody, beta F1, did not react with 26 B-cell lymphomas, 1 Ki-1 lymphoma or 6 Hodgkin's disease. This anti-TCR delta chain antibody, TCR delta 1, did not react with any type of malignant lymphoma. Although TCR beta and CD3 were co-expressed in normal lymphoid tissues and most T-cell lymphomas, 3 cases of CD3+ CD4+ CD8- T-cell lymphoma failed to express TCR beta. TCR beta and Ig JH gene configurations in malignant lymphomas were examined by Southern hybridization. Although each of 9 T-cell lymphomas had a rearranged TCR beta locus, TCR beta gene rearrangement in the 3 cases of beta F1- CD3+ T-cell lymphomas was demonstrated by Southern blot. No transcripts of the TCR beta gene could be found in 2 out of the 3 beta F1- CD3+ T-cell lymphomas by Northern blot, indicating the lack of TCR beta protein expression to be due to non-transcription of the TCR gene. Loss of TCR beta proteins in these T-cell lymphomas is thus quite likely to be associated with T-cell tumour activation and progression, since 3 beta F1- CD3+ T-cell lymphomas expressed CD25 (interleukin-2 receptor) to a high degree.
通过与T细胞受体(TCR)β链或TCRδ链反应的单克隆抗体,采用免疫组织化学方法检测恶性淋巴瘤中T细胞受体(TCR)的表达。在47例非霍奇金淋巴瘤中,有16例表达TCRβ。其中包括15例T细胞淋巴瘤和1例Ki-1淋巴瘤。抗TCRβ链抗体βF1与26例B细胞淋巴瘤、1例Ki-1淋巴瘤或6例霍奇金病均无反应。抗TCRδ链抗体TCRδ1与任何类型的恶性淋巴瘤均无反应。尽管TCRβ和CD3在正常淋巴组织和大多数T细胞淋巴瘤中共同表达,但有3例CD3+CD4+CD8-T细胞淋巴瘤未表达TCRβ。通过Southern杂交检测恶性淋巴瘤中TCRβ和Ig JH基因构型。尽管9例T细胞淋巴瘤中的每一例都有重排的TCRβ基因座,但Southern印迹法证实了3例βF1-CD3+T细胞淋巴瘤中存在TCRβ基因重排。Northern印迹法在3例βF1-CD3+T细胞淋巴瘤中的2例中未发现TCRβ基因转录本,表明TCRβ蛋白表达缺失是由于TCR基因未转录所致。因此,这些T细胞淋巴瘤中TCRβ蛋白的缺失很可能与T细胞肿瘤的激活和进展有关,因为3例βF1-CD3+T细胞淋巴瘤高度表达CD25(白细胞介素-2受体)。